Caricamento...
GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
INTRODUCTION: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin’s lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. CASE REPORT: The...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Healthcare Communications
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3510425/ https://ncbi.nlm.nih.gov/pubmed/23205326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-012-0003-9 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|